Galluzzo et al. (30) reported that brodalumab for psoriasis antagonizes signaling from IL-25, IL-17A, IL-17F, and IL-17A/F by blocking the IL-17 receptor A, which provides a new idea for the treatment of BP. Here, IL25 is linked to psoriasis.